Physician profile
Levente E Erdos
NPI 1659473197
$2,109.30
in general payments reported to CMS, 2019-2025
22 companies · $336 in 2025
The $336 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $437 · 2020: $146 · 2021: $250 · 2022: $346 · 2023: $140 · 2024: $454 · 2025: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $922 · Education: $8.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $921.97 |
| Education | $8.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $470.49 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $214.46 | 2019-2025 | |
| Glaxosmithkline, LLC. | $212.01 | 2021-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $185.23 | 2019-2024 | Breztri, Airsupra |
| Pharming Healthcare, INC. | $146.85 | 2021-2025 | Ruconest |
| Genentech USA, INC. | $126.69 | 2019-2022 | |
| Incyte Corporation | $111.25 | 2021-2023 | Opzelura |
| Grifols USA, LLC | $104.02 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $91.30 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $78.41 | 2020-2024 | Eohilia, Takhzyro |
| Pfizer INC. | $64.93 | 2022-2023 | |
| Blueprint Medicines Corporation | $52.25 | 2022-2024 | Ayvakit |
| Organon LLC | $42.27 | 2025 | Vtama |
| Covis Pharma Gmbh | $35.30 | 2022 | |
| Shire North American Group INC | $33.76 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $33.12 | 2025 | Hizentra |
| Phadia US INC. | $27.27 | 2023 | Immunocap |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.48 | 2021 | |
| Dermavant Sciences, INC. | $23.71 | 2024 | Vtama |
| Abbvie INC. | $13.68 | 2022 | |
| Bio Products Laboratory USA, INC. | $8.39 | 2023 | Gammaplex, Coagadex |
| Adma Biomanufacturing LLC | $7.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Levente Erdos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.